MANHATTAN ASSOCIATES INC (MANH) — Institutional Holders & Catalysts | BiotechEdge

MANHATTAN ASSOCIATES INC

MANH

Held by 1 specialist biotech fund

Specialists adding · Low short pressure

Share on X

BiotechEdge

Catalysts Convergence Insiders Cash Runway Research Pricing

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Support Terms Privacy Disclaimer

Fund Holdings

Eventide Asset ManagementHeld 4Q ↓

AI Signal

Signal Note: MANH Position Initiation

Eventide's new $346K position in Manhattan Associates—a supply chain software provider—signals conviction in logistics infrastructure benefiting from biotech/pharma distribution complexity, particularly relevant given ongoing GLP-1 and specialty drug scaling demands. This is a non-traditional biotech holding that reflects portfolio diversification into enabling infrastructure rather than direct drug development risk.

Unlock full AI analysis — 7-day free trial

4 quarters

Position Trend

May 15, 2025

$723K

1 fund

Aug 14, 2025

$1.3M

1 fund

Nov 14, 2025

$356K

1 fund

Feb 13, 2026

$346K

1 fund

-52% total institutional value over 4 quarters

Short Interest

Shorts covering

Short Shares

2.35M

Change

-22.4%

Days to Cover

3.3

% of Float

5.3%

Settlement

Mar 13, 2026

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementINCREASEFeb 13, 2026

Shares: 1,978Value: $346K

Eventide Asset ManagementDECREASENov 14, 2025

Shares: 1,715Value: $356K

Eventide Asset ManagementINCREASE

6,346 shares$1.3M

Eventide Asset ManagementNEW

4,177 shares$723K

+ 2more — see how much conviction went in

See the Full Story

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund UNP1 fund GPI1 fund PI1 fund IMMX1 fund BLDR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: